

This document provides you with key investor information about this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this fund. You are advised to read it so that you can make an informed decision about whether to invest.

Pictet - Biotech

(the "Compartment") is a compartment of Pictet (the "Fund")


P EUR (the "Share class") - ISIN LU0255977455

This Fund is managed by Pictet Asset Management (Europe) S.A. (the "Management Company"), part of the Pictet group

Objectives and Investment Policy

- The Compartment seeks capital growth by investing at least two-thirds of its assets in equities or similar securities issued by particularly innovative companies operating in the medical biotechnology sector.
- The eligible financial instruments are mainly international equities listed on a stock exchange. Geographically, the Compartment's investment universe is not restricted to a particular area (including emerging countries), however, given the particularly innovative nature of the pharmaceutical industry in North America and Western Europe, the vast majority of investments will be made in these areas.
- The Compartment may invest in China A shares through (i) the QFII ("Qualified Foreign Institutional Investor", subject to a maximum of 35% of its net assets), (ii) the RQFII ("Renminbi QFII") and/or (iii) the Shanghai-Hong Kong Stock Connect programme and/or (iv) the Shenzhen-Hong Kong Stock Connect programme and/or (v) any similar acceptable securities trading and clearing linked programmes or access instruments which may be available to the Compartment in the future. The Compartment may also use financial derivative instruments on China A shares.
- The Compartment may use financial derivative instruments for investment and hedging purposes. The Compartment may also invest in structured products.
- The Compartment is actively managed. The investment process is geared towards the rigorous analysis and evaluation of company fundamentals, with the aim of investing in companies that offer growth at a reasonable price. Only the best prospects benefiting from the growth of the biotechnology market are retained.
- The Share class does not distribute a dividend.
- The price of the Share class is calculated on a daily basis. Investors may redeem shares of the Compartment on any business day in Luxembourg, unless no underlying prices are available (market closed).
- The price of the Share class may be adjusted to ensure that rebalancing costs caused by subscriptions or redemptions are borne by investors responsible for those flows.
- Recommendation: the Compartment may not be appropriate for investors who plan to withdraw their money within 7 years.

Risk and Reward Profile



- The Share class is assigned to this risk category because of the price variations resulting from its currency and the nature of the Compartment's investments and strategy.
- The risk category shown is based on historical data and may not be a reliable indication for the future risk profile of the Share class.
- The risk category shown is not a target or a guarantee and may change over time.
- The lowest category does not mean a risk-free investment.
- The Compartment offers no capital guarantee or asset protection measures.
- The Compartment may be exposed to the following material risks which are not adequately captured by the synthetic risk indicator and may negatively impact its performance:

- Operational risk: losses may result from, for instance, human errors, system failures, incorrect valuation and safekeeping of assets.
- Counterparty risk: losses may occur when a counterparty does not honour its obligations related to instruments or contracts such as over-the-counter derivatives.
- Impact of financial techniques: the use of leverage may amplify losses and gains, and/or may not result in the intended exposure.
- Investments in emerging markets are generally more sensitive to risk events than those in developed markets. Such risk events may include changes in economic, political, fiscal and legal environment, as well as fraud.
- Investments in mainland China may be subject to capital restrictions and trading quotas, such as QFII and RQFII regimes for instance. The Compartment may suffer difficulties or delays in enforcing its rights in case of disputes.
- Chinese "Stock Connect" trading programs may be subject to additional risks related to the enforcement of ownership rights, clearing & settlement, trading quotas and operational issues.

Charges

One-off charges taken before or after you invest

Entry charge (in favor of the distributor)	Up to 5.00%
Exit charge (in favor of the distributor)	Up to 3.00%
Conversion charge (in favor of the distributor)	Up to 2.00%

This is the maximum that might be taken out of your money before it is invested or before the proceeds of your investment are paid out.

Charges taken from the Share class over a year

Ongoing charges	2.00%
-----------------	-------

Charges taken from the Share class under certain specific conditions

Performance fee	No performance fee
-----------------	--------------------

The charges you pay are used to pay the costs of running the Compartment, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

The **entry, conversion and exit charges** shown are maximum figures. In some cases you might pay less - you can find this out from your financial adviser or fund distributor.

The **ongoing charges** figure is based on expenses for the period ending on December 31st, 2017. This figure may vary from year to year. It excludes performance fees and portfolio transaction costs, except in the case of an entry/exit charge paid by the Compartment when buying or selling units/shares in another collective investment undertaking.

For more information about charges, please see section "Fund expenses" of the Fund prospectus, which is available at www.assetmanagement.pictet


Past Performance

The Share class has been launched on 5 December 2006 (Compartment on 5 December 2006).

Past performance is not a guide for future performance.

Performance figures do not include commissions or fees charged on equities trading.

Past performance has been calculated in EUR.



Practical Information

- Depositary bank: 15A, avenue J.F. Kennedy, L-1855 Luxembourg, Tel.: +352 467171-1, Fax: +352 467171-7667
- The Fund prospectus, the most recent annual and semi-annual reports and other information on the Fund can be obtained in English or French free of charge from the Fund's registered office, 15, avenue J.F. Kennedy, L-1855 Luxembourg, +352 46 71 71 1.
- The most recent share prices and other practical information can be obtained from the Fund's registered office.
- The tax laws of Grand Duchy of Luxembourg may have an effect on the investor's individual tax position.
- The Fund may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the Fund prospectus.
- This document describes one class of one of the Fund's compartments, while the prospectus and periodic reports cover the entire Fund.
- The assets and liabilities of the Fund's different compartments are segregated. As a result, the rights of investors and creditors in relation to any one compartment are restricted to the assets of that compartment.
- Provided they meet the access conditions, investors are entitled to exchange their shares for shares in another class of this Compartment or in another Fund compartment. Additional information on ways of exercising this right can be obtained from the Fund's registered office.
- The details of the up to date remuneration policy, including but not limited to a description of how remuneration and benefits are calculated, individuals responsible for awarding the remuneration and benefits including, as the case may be, the composition of the remuneration committee are available at www.group.pictet/PAMESA_UCITS_Remuneration_Policy and a paper copy is made available free of charge upon request at the Management Company's registered office.

The Fund is authorised in Luxembourg and supervised by the Commission de Surveillance du Secteur Financier. This key investor information is accurate as at 14 February 2018.